MedTrace Logo

ATROPOS: Survival Analysis of ICI-associated Myocarditis

NCT07633587 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-06-10

No results posted yet for this study

Summary

ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.

Conditions

  • Immune Checkpoint Inhibitor-associated Myocarditis

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2027-10-01
Completion
2027-10-01

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07633587 on ClinicalTrials.gov